Kontafarma China Holdings Ltd ( (HK:1312) ) has issued an update.
Kontafarma China Holdings Ltd has issued a profit warning, projecting a consolidated net loss between HK$79.2 million and HK$118.8 million for FY 2024, a significant increase from the previous year’s loss. The loss is attributed to the absence of a one-off gain from subsidiary disposal and an impairment on intangible assets due to slow recovery in its Taiwan fitness business. Despite this, the company anticipates an increase in overall revenue and gross profit, driven by rising demand for its pharmaceutical products and effective marketing strategies, as well as a rebound in its Singapore fitness business and reduced administrative expenses.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd operates in the pharmaceutical and fitness industries. The company is involved in the production and marketing of pharmaceutical products, particularly through Tongfang Pharmaceutical Group Co., Ltd. It also has a fitness business with a market presence in Taiwan and Singapore.
YTD Price Performance: -3.33%
Average Trading Volume: 1,620,545
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$161.8M
Learn more about 1312 stock on TipRanks’ Stock Analysis page.